Accueil
Détail de l'auteur
Documents disponibles écrits par cet auteur (291)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Rapport
European Centre for Disease Prevention and Control ; OEDT = EMCDDA | Stockholm : ECDC (European Centre for Disease Prevention and Control) | Technical report | 2011The aim of the literature review presented in this report was to provide evidence to inform the recommendations made by ECDC and the EMCDDA in the 2011 'Guidance on the prevention and control of infectious diseases among people who inject drugs'[...]Chapitre
This Selected issue looks both at drug use among socially excluded populations (prisoners, immigrants, the homeless, sex workers and vulnerable young people) and social exclusion among drug addicts.Rapport
OEDT = EMCDDA ; J. MOUNTENEY ; T. GROSHKOVA ; D. THANKI ; A. CUNNINGHAM ; M. RYCHERT | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014Concerns about the availability and use of methamphetamine in Europe have been growing for some time. Historically, the use of methamphetamine has been confined largely to the Czech Republic and Slovakia; however, recent signs of the spread of m[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. CHRISTIE ; S. SOLA ; A. ALMEIDA ; R. JORGE ; J. DE MORAIS ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2018In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency's early warning and risk-assessment activities. This report cov[...]Rapport
OEDT = EMCDDA ; J. MOUNTENEY ; M. EVANS-BROWN ; I. GIRAUDON | Lisbon : OEDT / EMCDDA | Technical reports | 2012The EMCDDA Trendspotter case study on Fentanyl in Europe was undertaken during September and October 2012. It culminated in an expert meeting in Lisbon on 9-10 October 2012. The aim of the study was to increase understanding of the availability [...]Rapport
OEDT = EMCDDA ; C. COSTA STORTI ; D. FRASQUILHO ; G. BURKHART ; M. MOREIRA | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014The economic crisis that Europe experienced in 2008 and later presented a grave challenge to public finances. Countries responded to this by undertaking fiscal consolidation. By examining public expenditure in the areas where most drug-related a[...]Rapport
Rapport
This report presents the overview of the drug phenomenon in France, covering drug supply, use and public health problems, as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided t[...]Rapport
In November 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide, commonly known as furanylfentanyl, through a joint assessment. Furanylf[...]Rapport
This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 23 May 2017. On the ba[...]Rapport
OEDT = EMCDDA ; ONUDC / UNODC | New York : UNODC/UNODCCP | Programme mondial d'évaluation de l'abus de drogues / Global Assessment Programme on drug abuse (GAP) | 2007The number of people seeking treatment for drug problems is a leading indicator of drug use patterns and prevalence. Data collected from this group offer a valuable 'window' onto an otherwise hidden population and a means of assessing the perfor[...]Rapport
Prices are an essential element of the illicit drug market, from both a supply and demand perspective. They are an indicator of drug availability and are an important tool for understanding the workings of drug supply mechanisms. They may also b[...]Rapport
OEDT = EMCDDA ; C. KROGER ; H. WINTER ; R. SHAW ; L. LEONE | Lisbon : OEDT / EMCDDA | Manuals | 2012The EMCDDA first published the Guidelines for the evaluation of drug prevention in 1998 to respond to a need expressed by professionals and policymakers to have a tool and stimulus to evaluate prevention interventions in Europe. These guidelines[...]Rapport
ENGLISH : The main objective of the guidelines is to provide a European audience with basic information on the options, elements and procedures of drug-related treatment evaluation. The target readership includes professionals working in treat[...]Rapport
Prevalence of problem drug use (PDU) is one of five key indicators used by the EMCDDA to provide more comparable, scientifically based estimates of the prevalence of more severe patterns of drug use that cannot be reliably measured by surveys. T[...]